Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00022375
DRKS00022375
Recruiting
未知

Role of liquid biopsy, analysis of circulating tumor cells and organoids in the diagnostic and therapy of upper-GI and hepato-pancreatico-bilary cancers (GI- and HPB-CA) - LiBiCO

niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg0 sites150 target enrollmentAugust 30, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC15C16C22C23C24C25Malignant neoplasm of oesophagusMalignant neoplasm of stomachMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of gallbladderMalignant neoplasm of other and unspecified parts of biliary tractMalignant neoplasm of pancreas

Overview

Phase
未知
Intervention
Not specified
Conditions
C15
Sponsor
niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg
Enrollment
150
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 30, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg

Eligibility Criteria

Inclusion Criteria

  • •Patients with GI\- and HPB\-CA

Exclusion Criteria

  • •Patients with poor condition who cannot tolerate chemotherapy and targeted therapy.
  • •Patients with impaired organ functions, heart failure (New York Heart Association III\-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.
  • •Patients diagnosed with other cancer within 5 years.
  • •Patients who are pregnant or breastfeeding.
  • •Patients enrolled in other clinical trials or incompliant of regular follow up.
  • •Patients who did not provide an informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)Ethmoid Sinus TumorAdenocarcinomaCirculating Tumor Cell
NCT06090214University Hospital, Montpellier42
Completed
Not Applicable
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTCPancreatic Ductal Adenocarcinoma (PDAC)
NCT03032913University Hospital, Bordeaux52
Unknown
Not Applicable
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung CancerHealthyPulmonary Nodule
NCT04156360Shanghai Pulmonary Hospital, Shanghai, China150
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-511317-38-00Fundacion GECP33
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-002369-36-ESFundación GECP30